Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer
'We're thrilled to welcome Dallan to Vor Bio at this important inflection point,' said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board. 'His track record of building high-performing commercial organizations and executing successful product launches will be instrumental as we prepare for potential commercialization of telitacicept and shape our broader growth strategy.'
Mr. Murray brings more than 25 years of experience leading commercial strategy, global product launches, and customer-facing organizations in biotechnology and pharmaceutical companies. He joins Vor Bio from Sarepta Therapeutics, where he most recently served as Executive Vice President, Chief Customer Officer. In that role, he led the commercial and medical affairs organizations, along with the international business unit. Under his leadership, Sarepta achieved approximately $1.8 billion in net product revenue in 2024. While at Sarepta he oversaw multiple product launches, including the launch of the first RNA therapy and first gene therapy for duchenne muscular dystrophy. Over the course of his career, Mr. Murray has led or supported more than a dozen product launches, including INCIVEK at Vertex Pharmaceutics, Inc., the fastest launch to $1 billion in biotech history at the time, and multiple global rollouts at Gilead Sciences, Inc., Biogen Inc., and Johnson & Johnson. At Gilead, he oversaw the launch of VIREAD in hepatitis B and maintained leadership in the HBV market. While at Biogen, he played a key role in the reintroduction and global commercialization of TYSABRI for multiple sclerosis, helping drive adoption across North America and international markets. Mr. Murray holds an MBA from Queen's University in Ontario, Canada, and a Bachelor of Commerce from the University of Alberta.
'Vor Bio is building a company with great potential,' said Mr. Murray. 'With telitacicept already approved in China for multiple autoimmune indications and now advancing through global Phase 3 development, I look forward to the opportunity to bring a much-needed treatment to patients around the world. I'm excited to join the team and help lay the commercial and strategic foundation for long-term success.'
About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words 'aim,' 'anticipate,' 'can,' 'continue,' 'could,' 'design,' 'enable,' 'expect,' 'initiate,' 'intend,' 'may,' 'on-track,' 'ongoing,' 'plan,' 'potential,' 'should,' 'target,' 'update,' 'will,' 'would,' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include Vor Bio's statements regarding Vor Bio's development and commercialization plans for telitacicept, its ability to change the treatment landscape for patients with autoimmune conditions and other statements that are not historical fact. Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors. These and other risks are described in greater detail under the caption 'Risk Factors' included in Vor Bio's most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
28 minutes ago
- Globe and Mail
Essential Thrombocythemia Pipeline Outlook Report 2025: Key 6+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's, 'Essential Thrombocythemia Pipeline Insight 2025' report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Essential Thrombocythemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Essential Thrombocythemia Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ Essential Thrombocythemia Pipeline Outlook Report In August 2025:- Icahn School of Medicine at Mount Sinai conducted a phase II study to assess the efficacy, safety, and tolerability of Reparixin in patients with DIPSS intermediate-2, or high-risk primary Essential Thrombocythemia (PMF), post essential thrombocythemia/polycythemia vera related MF (Post ET/PV MF) after prior treatment, and those who are ineligible or refuse treatment, with a Janus kinase inhibitor (JAKi). 26 patients will be enrolled. Eligible patients will receive oral reparixin three times daily on a 4-week cycle for a core study period of 6 cycles (24 weeks). DelveInsight's Essential Thrombocythemia pipeline report depicts a robust space with 6+ active players working to develop 6+ pipeline therapies for Essential Thrombocythemia treatment. The leading Essential Thrombocythemia Companies such as PharmaEssentia, Imago BioSciences, Novartis, Constellation Pharmaceuticals and others. Promising Essential Thrombocythemia Pipeline Therapies such as Anagrelide, Hydroxyurea, IMG-7289, Bomedemstat, Busulfan, Thromboreductin, Ropeginterferon alfa-2b-njft (P1101) and others. Discover how the Essential Thrombocythemia treatment paradigm is evolving. Access DelveInsight's in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Essential Thrombocythemia Clinical Trials and Studies Essential Thrombocythemia Emerging Drugs Profile Ropeginterferon alfa-2b: PharmaEssentia Ropeginterferon alfa-2b is a novel, long-acting, mono-pegylated proline interferon (ATC L03AB15). Its pharmacokinetic properties offer a new level of tolerability. Ropeginterferon alfa-2b is designed to be self-administered subcutaneously with a pen once every two weeks, or monthly during long-term maintenance. This treatment schedule is expected to lead to overall better safety, tolerability and adherence compared to conventional pegylated interferons. PharmaEssentia Corporation is developing a pegylated (PEG) IFN-α product, P1101, for the treatment of ET. The Phase III multi-site, open-label, randomized, active-controlled study will compare the efficacy, safety, and tolerability and pharmacokinetics of P1101 as second line therapy for ET as compared with anagrelide, a commonly used oral platelet-reduction therapy. IMG-7289: Imago Biosciences IMG-7289 (Bomedemstat) is an orally available small molecule, discovered and developed by Imago BioSciences that inhibits lysine-specific demethylase 1 (LSD1 or KDM1A), an enzyme shown to be vital in cancer stem/progenitor cells, particularly neoplastic bone marrow cells. In non-clinical studies, bomedemstat demonstrated robust in vivo anti-tumor efficacy across a range of myeloid malignancies as a single agent and in combination with other therapeutic agents. The drug is being evaluated in Phase II clinical trial to treat patients with Essential thrombocythaemia, Essential Thrombocythemia, and Polycythaemia Vera. The Drug has been granted orphan and fast track designation from US FDA. The Essential Thrombocythemia Pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Essential Thrombocythemia with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Essential Thrombocythemia Treatment. Essential Thrombocythemia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Essential Thrombocythemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Essential Thrombocythemia market. Get a detailed analysis of the latest innovations in the Essential Thrombocythemia pipeline. Explore DelveInsight's expert-driven report today! @ Essential Thrombocythemia Unmet Needs Essential Thrombocythemia Companies PharmaEssentia, Imago BioSciences, Novartis, Constellation Pharmaceuticals and others. Essential Thrombocythemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Parenteral Intravenous Subcutaneous Topical Molecule Type Essential Thrombocythemia Products have been categorized under various Molecule types such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Product Type Download DelveInsight's latest report to gain strategic insights into upcoming Essential Thrombocythemia Therapies and key Developments @ Essential Thrombocythemia Market Drivers and Barriers, and Future Perspectives Scope of the Essential Thrombocythemia Pipeline Report Coverage- Global Essential Thrombocythemia Companies- PharmaEssentia, Imago BioSciences, Novartis, Constellation Pharmaceuticals and others. Essential Thrombocythemia Pipeline Therapies- Anagrelide, Hydroxyurea, IMG-7289, Bomedemstat, Busulfan, Thromboreductin, Ropeginterferon alfa-2b-njft (P1101) and others. Essential Thrombocythemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Essential Thrombocythemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Essential Thrombocythemia drug development? Find out in DelveInsight's exclusive Essential Thrombocythemia Pipeline Report—access it now! @ Essential Thrombocythemia Emerging Drugs and Major Companies Table of Contents Introduction Executive Summary Essential Thrombocythemia: Overview Pipeline Therapeutics Therapeutic Assessment Late Stage Products (Phase III) Ropeginterferon alfa-2b: PharmaEssentia Mid Stage Products (Phase II) IMG-7289: Imago Biosciences Early stage products (Phase I/II) Drug Name: Company Name Inactive Products Essential Thrombocythemia Key Companies Essential Thrombocythemia Key Products Essential Thrombocythemia- Unmet Needs Essential Thrombocythemia- Market Drivers and Barriers Essential Thrombocythemia- Future Perspectives and Conclusion Essential Thrombocythemia Analyst Views Essential Thrombocythemia Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
28 minutes ago
- Globe and Mail
Do Options Traders Know Something About Royal Gold Stock We Don't?
Investors in Royal Gold, Inc. RGLD need to pay close attention to the stock based on moves in the options market lately. That is because the Dec. 19, 2025 $70 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy. What do the Analysts Think? Clearly, options traders are pricing in a big move for Royal Gold shares, but what is the fundamental picture for the company? Currently, Royal Gold is a Zacks Rank #1 (Strong Buy) in the Mining – Gold industry that ranks in the Top 21% of our Zacks Industry Rank. Over the last 30 days, no analyst increased the earnings estimates for the current quarter, while one has dropped the estimates. The net effect has taken our Zacks Consensus Estimate for the current quarter from $1.65 per share to $1.70 in that period. Given the way analysts feel about Royal Gold right now, this huge implied volatility could mean there's a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected. Looking to Trade Options? Check out the simple yet high-powered approach that Zacks Executive VP Kevin Matras has used to close recent double and triple-digit winners. In addition to impressive profit potential, these trades can actually reduce your risk. Zacks Names #1 Semiconductor Stock This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Royal Gold, Inc. (RGLD): Free Stock Analysis Report
Globe and Mail
an hour ago
- Globe and Mail
Fortinet Stock Before Q2 Earnings: Buy Now or Wait for Results?
Fortinet FTNT is slated to report second-quarter 2025 results on Aug. 6. For the second quarter of 2025, Fortinet expects revenues in the range of $1.59-$1.65 billion. It anticipates non-GAAP earnings per share in the band of 58-60 cents. The Zacks Consensus Estimate for second-quarter revenues is pegged at $1.62 billion, suggesting year-over-year growth of 12.9%. The consensus mark for earnings is pinned at 59 cents per share, which has remained unchanged over the past 30 days. The estimate indicates a year-over-year increase of 3.51%. FTNT Earnings Surprise History In the last reported quarter, the company delivered an earnings surprise of 9.43%. The company's earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 23.83%. Fortinet, Inc. Price and EPS Surprise Fortinet, Inc. price-eps-surprise | Fortinet, Inc. Quote Earnings Whispers for DDOG Our proven model does not predict an earnings beat for Fortinet this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter. FTNT has an Earnings ESP of 0.00% and carries a Zacks Rank #2 at present. You can see the complete list of today's Zacks #1 Rank stocks here. Factors Shaping Upcoming Results of FTNT Fortinet entered the second quarter of 2025 with exceptional momentum following a record-setting first quarter that successfully delivered 14% revenue growth to $1.54 billion and achieved a record operating margin of 34%. The company's strong first-quarter performance was driven by a record free cash flow of $783 million and robust growth in strategic focus areas, with Unified SASE billings increasing 18% and accounting for 25% of total business, while AI-driven secure operations billings surged 29% to represent 10% of the business. During the second quarter, Fortinet launched the highly anticipated FortiGate 700G series, a next-generation firewall that delivered up to 7x higher firewall throughput and 4x better threat protection compared to competitors while consuming 7x less power per gigabit. This innovative product, powered by Fortinet's proprietary Network Processor 7 and Security Processor 5 ASIC technologies, incorporates advanced AI-powered threat detection through FortiAI-Protect and post-quantum cryptography readiness, positioning the company to capture increased market share in the campus security segment. The company further strengthened its comprehensive product portfolio in June with the strategic unveiling of its advanced AI-powered workspace security suite, including FortiMail Workspace Security enhancements and powerful FortiDLP upgrades that extended protection beyond email to include browser and collaboration security. July brought additional validation when Fortinet was recognized as a Leader in the 2025 Gartner Magic Quadrant for SASE Platforms and ranked #1 in the Secure Branch Network Modernization use case. Building on the first-quarter's exceptionally strong new customer acquisition of more than 6,300 new logos representing 14% growth, driven by strategic channel partner investments, and the company's maintained position as the number one deployed firewall vendor worldwide and market leader in SD-WAN and OT security, these highly strategic product launches and significant industry recognition positioned Fortinet for strong second-quarter 2025 financial results and demonstrate continued strong market leadership. While the competitive landscape remains fierce from rivals like Palo Alto Networks PANW, Zscaler ZS and CrowdStrike CRWD, Fortinet's focus on reducing complexity, expanding sales capacity, and accelerating SASE adoption positions it for durable long-term growth, making it a smart buy choice for investors ahead of second-quarter 2025 results. Top-Line Growth Estimates for Q2 Our model estimate for second-quarter 2025 Americas revenues is pegged at $664.8 million, indicating 11.7% growth from the figure reported in the year-ago quarter. Our model estimate for Asia Pacific and Japan revenues is pinned at $324.6 million, indicating growth of 18.6% from the figure reported in the year-ago quarter. Our model estimate for Europe, Middle East and Africa revenues is pegged at $629.5 million, suggesting a 11.4% decrease from the figure reported in the year-ago quarter. Our model estimate for second-quarter 2025 total billings is pegged at $1.73 billion, indicating a 12.3% decrease from the figure reported in the year-ago quarter. FTNT Price Performance & Stock Valuation Shares of Fortinet have gained 4.9% in the year-to-date period, outperforming the Computer and Technology sector and the S&P 500 index's decline of 9.1% and 5.7%, respectively. The company's outperformance can be attributed to its establishment as a leading provider of SASE solutions. SASE adoption is accelerating across enterprises, and to keep pace, Fortinet continuously enhances FortiOS, integrating advanced networking and security into a unified platform. FTNT's YTD Price Performance Fortinet's valuation may be a concern for some investors. The stock is trading at a significant premium compared to the broader Zacks Security industry. As of the latest data, FTNT's Price/Book ratio hovers around 37.97, well above the industry's 17.52, reflecting investors' high growth expectations. The Value Score of F further reinforces a stretched valuation for Fortinet at this moment. FTNT Trades at a Premium Investment Considerations Fortinet represents a compelling investment opportunity despite premium valuation, as the company's record-setting first-quarter performance with 34% operating margins and strategic product launches position it for exceptional second-quarter results. The groundbreaking FortiGate 700G series delivers 7x higher performance and AI-powered security innovations demonstrate sustainable competitive advantages that justify premium pricing. With 18% Unified SASE growth, market-leading positions in firewalls and SD-WAN, and Gartner Magic Quadrant Leadership recognition, Fortinet continues expanding its market share against competitors. Strong customer acquisition exceeding 6,300 new logos and robust free cash flow generation provide a foundation for continued outperformance, making the current valuation attractive before anticipated second-quarter strength. Conclusion Fortinet's exceptional first-quarter momentum, groundbreaking FortiGate 700G launch, and market-leading SASE growth create compelling catalysts for strong second-quarter performance. With record margins, robust customer acquisition, and continued innovation leadership, investors should strategically capitalize on current opportunities before anticipated earnings strength potentially drives significant stock appreciation heading into the August results. Zacks Names #1 Semiconductor Stock This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Fortinet, Inc. (FTNT): Free Stock Analysis Report Palo Alto Networks, Inc. (PANW): Free Stock Analysis Report Zscaler, Inc. (ZS): Free Stock Analysis Report CrowdStrike (CRWD): Free Stock Analysis Report
